PRECLINICAL STUDIES TO ASSESS ACUTE AND CHRONIC TOXICITIES OF A CANDIDATE DRUG BASED ON COMPLEMENT C3 NEODETERMINANT RECOMBINANT HUMANIZED ANTIBODY FOR TREATMENT OF TRAUMATIC BRAIN INJURIES

A.V. Trofimov,A.V. Zhakhov,S.V. Rodin,N.P. Gorbunov, A.V. Petrov,N.V. Pigareva,G.V. Aleksandrov,M.S. Zakharov,А.S. Kiryanova,О.E. Khuttunen,I.V. Bendt,A.E. Krylova,A.M. Ischenko

http://eng.biomos.ru/conference/articles.htmBIOTECHNOLOGY: STATE OF THE ART AND PERSPECTIVES（2021）

引用 0|浏览3

暂无评分

摘要

A drug based on complement C3 neodeterminant recombinant humanized antibody for the treatment of traumatic brain injuries belongs to the class III of low-risk drugs.

查看译文

关键词

recombinant humanized antibody

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要